Background: To evaluate the role of definitive radiotherapy using higher-thanstandard-dose radiation of 50 Gy for carcinoma of the cervical esophagus (CCE). Methods: We reviewed 79 patients with stage I-III CCE, treated between 2000 and 2012. Patients received 5-fluorouracil/cisplatin-based chemotherapy concurrently and were divided into high-dose (≥59.4 Gy, n = 44) and standard-dose (<59.4 Gy, n = 35) groups. Results: The median follow-up was 35 months for surviving patients. The highdose group had significantly better 3-year local (90.0% vs 60.4%, P = .001) and locoregional (70.4% vs 45.3%, P = .04) control. Progression-free (45.4% vs 37.5%, P = .32) and overall (58.4% vs 49.1%, P = .69) survival rates were not different. High-dose radiation was an independent prognostic factor for locoregional control (P = .04). No differences in late toxicities (esophageal stenosis or tracheoesophageal fistula) were observed. Conclusion: High-dose radiation for CCE improves local and locoregional control, without increasing severe toxicities.
The surgical option for CCE is usually laryngo-pharyngoesophagectomy; however, R0 resection is difficult to achieve. Combined with the high severe surgical morbidity and inhospital mortality rates, the 5-year survival rates following surgery are as low as 14%-16%. 3 Concurrent chemoradiotherapy (CCRT) is recommended as the standard of care for patients with CCE. [4] [5] [6] [7] [8] The RTOG 94-05 trial compared CCRT of 50.4 Gy with 64.8 Gy concurrently given with same chemotherapy regimen among patients with locally advanced esophageal cancer; the higher dose conferred no significant advantage. 9, 10 The current recommended dose for esophageal cancer is 50. 4 Gy, whether administered as preoperative, postoperative, or definitive radiotherapy (RT). 11 Because of the anatomic proximity of the esophagus to the hypopharynx, which receives up to 70 Gy for definitive treatment, and because CCRT is often the sole curative treatment option for CCE, a radiation dose higher than the standard 50 Gy is suggested for CCE. However, few studies have reported comparative analyses of higher versus standard-dose RT for CCE. In this study, we investigated the role of higher-thanstandard-dose radiation for CCE. The aims were to determine whether dose escalation is associated with advantages in terms of local control and survival, and whether treatment-related toxicities are increased with higher doses.
| MATERIALS AND METHODS

| Study population
A list of patients diagnosed with esophageal cancer between 2000 and 2012 was extracted from an institutional cancer registry; 410 patients were identified. Eligibility criteria included the following: primary tumor located above the sternal notch, clinical stage I-III according to AJCC 7th edition, 5-fluorouracil/cisplatin-based CCRT, and definitive treatment aim. Patients were excluded from the study for the following reasons: cancer in the thoracic esophagus (n = 151), not completing planned treatment (n = 80), diagnosed with synchronous hypopharyngeal cancer (n = 52), palliative treatment aim (radiation dose <45 Gy, n = 36), and subsequent surgical resection (n = 12). After all exclusions, the data of 79 patients were analyzed. The procedures followed in this retrospective study were in accordance with the Helsinki Declaration of 1975, as revised in 2000, and the study was approved by our Institutional Review Board (IRB # 4-2017-0027).
| Pretreatment evaluation and treatment details
Pretreatment evaluation included a complete history and physical examination. Laboratory studies included a complete blood cell count and serum chemistry profile. For staging workup, patients underwent endoscopic biopsy and imaging studies such as CT and endoscopic ultrasonography. Positron emission tomography (PET), bone scans, and abdominal CT were performed in 80%, 27%, and 22% of the patients for systemic evaluation, respectively. PET-CT was performed in 91% for the high-dose group and 73% for the standard-dose group.
RT was delivered using megavoltage photons (≥6 MV). All patients received treatment according to a conventional fractionation schedule (5 days per week, 1.8-2.0 Gy/fraction daily). Cone down techniques were used in all patients. The target volume was delineated using either MIM software (Cleveland, Ohio) or the Pinnacle Radiotherapy Planning System (Phillips Medical System, Andover, Massachusetts). The target volume was delineated on simulation CT images fused with PET images. The gross tumor volume included the primary esophageal cancer and metastatic lymph node(s). The initial clinical target volume (CTV) included the gross tumor volume plus a margin of 4 cm longitudinally and 1-2 cm radially. The initial CTV also included both supraclavicular node areas, regarded as elective nodal irradiation. The planning target volume was the CTV plus a 0.7 cm margin. Using threedimensional conformal radiotherapy (3D-CRT), the initial CTV was treated using anterior-posterior opposite fields with a dose of up to 30.6-45 Gy to reduce the lung irradiation volume. Taking irradiation of the lung and spinal cord into consideration, the dose of the cone down target volume was determined. The cone down CTV encompassed the primary esophageal cancer plus a margin of 2 cm longitudinally and excluded the elective nodal area. Cone down CTV was administered via 3, 4, or 5 multiports to reduce the spinal cord dose. Using intensity modulated radiotherapy (IMRT), the simultaneously integrated boost technique was used. Planning target volume 1, which encompassed the gross tumor volume plus a 0.7 cm margin, received 2.1 Gy per fraction, and planning target volume 2, which encompassed the CTV plus a 0.7 cm margin, received 1.7 Gy per fraction. A sample case of RT field ( Figure 1A 
| Analysis details
To monitor treatment-related toxicities throughout all phases of treatment, each patient was examined at least once a week-more often if clinically indicated. Treatment-related toxicities were graded according to the Common Toxicity Criteria for Adverse Events version 4.0.
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The treatment response, assessed according to Response Evaluation Criteria for Solid Tumors version 1.1, 13 was determined 1, 3, and 6 months after completing CCRT by endoscopy and imaging modalities such as CT and/or PET-CT.
Complete response was defined as the disappearance of all target lesions. Partial response was defined as a decrease in the sum of the longest diameters of the target lesions of at least 30%, with the corresponding baseline values used as reference values. Stable disease was defined as shrinkage not meeting the criteria for partial response or for progressive disease, taking as the reference the smallest sum of the longest diameter since the treatment started. Progressive disease was defined as either an increase of at least 20% in the sum of the longest diameters of the target lesions, with the corresponding smallest sum recorded since the treatment initiation used as the reference, or the appearance of one or more new lesions. Patterns of failure were determined using the site of first failure. Failure was defined as either the reappearance of a lesion that had shown complete response or the appearance of any new lesion. Local failure was defined as failure occurring within the primary esophageal cancer and metastatic lymph node(s). Regional failure was defined as failure occurring in the elective nodal areas. Distant failure involved any site beyond the primary tumor and regional lymph nodes.
| Statistical analysis
Statistical analyses were conducted using IBM SPSS version 20.0 (IBM Corp., Armonk, New York). Potential prognostic characteristics between higher and standard-dose radiation were compared using the chi-square test. We used the Kaplan-Meier method to calculate overall survival (OS), locoregional control (LRC), and progression-free survival (PFS); differences between the curves were analyzed using the log-rank test. Prognostic factors for survival were analyzed by multivariate analyses using Cox's proportional hazards model. Statistical significance was defined as P < .05.
| RESULTS
| Patients' characteristics
Patients were divided into 2 groups according to the radiation dose: a high-dose group and a standard-dose group. The high-dose group (n = 44) received ≥59.4 Gy whereas the standard-dose group (n = 35) received <59.4 Gy. The median doses used in the high-dose and standard-dose groups were 63 Gy (range, 59.4-75.4 Gy) and 50.4 Gy (range, 46-57.6 Gy), respectively. The patients' characteristics are summarized in Table 1 . The 2 groups were well balanced for age, sex, Eastern Cooperative Oncology Group performance status, pathology type, clinical T-classification, and clinical N-classification.
The participants' treatment characteristics are summarized in Table 2 . All patients in the standard-dose group and 93% of patients in the high-dose group were treated with 3D-CRT. There were no differences in terms of chemotherapy regimen used and the proportion of participants who received maintenance chemotherapy. There were 25% of patients who received other chemotherapy. Five patients in the high-dose group and 6 in the standard-dose group were treated with TS-1/cisplatin-based chemotherapy. Three patients were treated with 5-fluorouracil monotherapy and 3 with cisplatin monotherapy in the high-dose group, and 5 patients were treated with cisplatin monotherapy in the standard-dose group.
| Survival analysis and prognostic factors
The median duration of follow-up was 18 months (range, 2-130) for all patients and 35 months (range, 5-130) for those still alive at the time of analysis. The 3-year OS and PFS rates for all patients were 53.9% and 41.3%, respectively. There were no significant differences in 3-year OS rates (58.4% vs 49.1%, respectively, P = .69, Figure 2 ) or in 3-year PFS rates (45.4% vs 37.5%, respectively, P = .32) between the high-dose and standard-dose groups. However, the rates of local control (90.0% vs 60.4%, P = .001) and LRC (70.4% vs 45.3%, P = .04, Figure 3 ) at 3 years were significantly better in the high-dose than in the standard-dose group. The 3-year distant control rates for the high-dose and standard-dose groups were 69.2% and 82.9%, respectively (P = .21).
The prognostic factors associated with LRC and OS are summarized in Table 3 . Univariate analysis revealed that pathologic type, radiation dose, chemotherapeutic regimen, and use of maintenance chemotherapy were significant prognostic factors associated with LRC. In the multivariate analysis, a diagnosis of squamous cell carcinoma and high-dose radiation were associated with improved rates of LRC. In the univariate analysis for OS, performance status, T-classification, and the use of maintenance chemotherapy were significant prognostic factors, but in the multivariate analysis, early T-classification was the only factor associated with better OS. There was no significant difference in OS rates between the standard-dose and high-dose RT groups.
| Patterns of failure and toxicity
The patterns of failure according to dose group are summarized in Table 4 . The high-dose group demonstrated a lower incidence of local (29% vs 5%, P = .007) and locoregional (45% vs 15%, P = .007) failure than did the standard-dose group. A greater proportion of patients in the high-dose group than in the standard-dose group had distant failure (14% vs 6%, respectively), but the difference was not significant.
The incidence of esophageal stenosis requiring balloon dilatation was greater in the high-dose group, but the difference was not significant (14% vs 9%, P = .72). There was no difference between the high-dose and standard-dose groups in terms of the proportion of patients developing a tracheoesophageal fistula requiring intervention (5% vs 6%, respectively, P > .99). Apart from these adverse events, the treatments were well tolerated in all patients. No treatmentrelated toxicities of grade 4 or higher occurred in either treatment group.
| DISCUSSION
In this study of the role of higher-than-standard-dose radiation in the treatment of CCE, patients who received a higher total radiation dose (≥59.4 Gy) had significantly better LRC, without experiencing any severe toxicities. In the context of definitive CCRT, 50.4 Gy with conventional fractionations is generally considered inadequate to control gross tumors. 14 In the RTOG 94-05 trial that compared 64.8 Gy with 50.4 Gy for treating esophageal cancer, no significant differences in OS and LRC between the high-dose and standarddose treatment arms were reported. 10 One of the main reasons that a dose-escalation study fails is treatment-related toxicity. In the RTOG 94-05 trial, 11 treatment-related deaths occurred in the high-dose arm; 2 such deaths occurred in the standard-dose arm. However, 7 of the deaths in the high-dose arm occurred in patients who received ≤50.4 Gy, and only 1 patient died because of a gastrointestinal fistula. Moreover, 3 patients died after receiving <10 Gy; all 3 deaths were from cardiac causes, which may be considered irrelevant to RT toxicity. Because of the increased incidence of treatment-related deaths in the high-dose arm, only 67% of patients in that arm received RT according to protocol (compared with 83% of patients in the standard-dose arm). In the period during which RTOG 94-05 was conducted, patients were treated with 2-dimensional RT techniques using large treatment volumes, contributing to increased lung toxicity. In current practice, smaller target volumes are used and the use of 3D-CRT or IMRT can significantly reduce radiation toxicity to normal tissues. Finally, no analysis was performed according to tumor location; the types of radiation toxicity that occur may differ between CCE and thoracic esophageal cancer. Radiation dose escalation for esophageal cancer is an issue of ongoing debate in radiation oncology. According to analyses based on data from the National Cancer Database, 15 17 Patients in the higher dose group had better 3-year local control and disease-free survival rates than those in the lower-dose group (36% vs 19% and 25% vs 10%, respectively). However, limitations of their study include that only 26 patients were treated with high-dose radiation and fractionation schedules were not uniform. Results from our previous report suggest that high-dose radiation may be beneficial in patients with stage II-III esophageal cancer. 18 In that study, 126 patients were treated with CCRT: 49 received <60 Gy and 77 received ≥60 Gy. The high-dose group showed significantly improved 2-year LRC (69% vs 32%) and 2-year PFS (47% vs 20%) rates relative to the standard-dose group. However, there was no significant difference in OS between groups. A more recent report from our institution suggests that high-dose radiation confers an OS benefit. 19 In that study of 236 patients, participants in the high-dose group had a significantly better 2-year LRC rate, median PFS duration, and median OS duration (35.1 months vs 22.3 months). Using 2-dimensional RT, an anterior-posterior/posterior-anterior field was applied, increasing the probability of toxicity. Our retrospective data on dose escalation for esophageal cancer suggest that, with the development of newer RT techniques, namely 3D-CRT and IMRT, dose escalation with smaller fields could yield better outcomes including improved local control and survival. The treatment of CCE differs from that of thoracic esophageal cancer because different anatomic organs are at risk. With respect to the cervical esophagus, there are a small number of organs at risk of radiation injury, and only small portion of the lung is irradiated. There are only a few studies on CCE. Tong et al. reported results of 107 patients treated for CCE. 20 The management strategies that the authors adopted were either primary surgical resection followed by postoperative RT or definitive CCRT offered as an alternative for patients who declined surgery. The surgical strategy was pharyngo-laryngo-esophagectomy and cervical lymphadenectomy including cervical node levels II-IV for patients with confirmed cervical nodal metastasis. For definitive RT, 3D-CRT of 60-68 Gy with concurrent 5-fluorouracil/ Data are presented as n (%).
cisplatin was used. The median survival duration and 2-year survival rates were 20 months and 38%, respectively, for patients undergoing surgery and 25 months and 47%, respectively, for patients undergoing CCRT. Five patients died within 1 month postsurgery, and another died from a carotid blowout 6 months after RT. Table 5 gives an overview of the published outcomes of CCE patients treated with CCRT. The results of the present study suggest that higher-than-standard-dose radiation results in improved local control and LRC rates without causing severe treatment-related toxicities. However, the advantage in LRC did not lead to statistically significant improvements in PFS or OS. Although the current study reviewed 79 patients which is a large number for a rare disease such as CCE, the number was not large enough to show statistical significance in PFS and OS. Second, the high-dose group showed a higher incidence rate of distant failures which would have resulted in lowering PFS and OS despite higher LC in the high-dose group. Finally, the high-dose group had a higher number of T3/4 cases than the standard dose. Effective chemotherapeutic regimens and maintenance chemotherapy could confer a survival advantage, such as PFS and OS.
The current study has several limitations. The chemotherapy regimens used for concurrent and maintenance chemotherapy were not uniform; this may have influenced tumor response and distant metastasis rates. Furthermore, a larger number of patients were node-negative in the high-dose than in the standard-dose group, although this may be balanced by the excess of T3/4 cases in the high dose arm as well. Finally, due to the retrospective nature of the study, the true incidence of treatment-related toxicities could have been underestimated. There were 80 patients excluded from the analysis since they did not complete the planned treatment course. Thirty-six (45%) patients had no record of why the planned treatment was not completed, and most of these patients were treated in the years when electronic medical record system was not available. Twenty (25%) patients were transferred to other hospitals according to the patients' wish to be treated near their homes. Twenty-four (30%) patients did not finish planned treatment due to treatment-related toxicities. Toxicities occurred at relatively low RT doses (less than 36 Gy) and most common toxicity was chemotherapyinduced pancytopenia. Treatment-related toxicities are summarized in Supporting Information Table S1 . Twenty (83%) of these patients were older than 65 years and 18 (75%) were node positive. Half of the patients had poor performance status (ECOG 2-3). The median radiation dose when these toxicities occurred was 23.4 Gy (range, 9-41.4 Gy). Nonetheless, the current study evaluated a relatively large number of CCE patients, who were treated according to a single institutional protocol.
| CONCLUSION
Higher-than-standard-dose radiation for CCE results in improved local control and LRC rates without causing severe treatment-related toxicities. A prospective study is warranted to evaluate survival benefits of higher dose radiation for CCE.
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